ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD-8055. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar

Bibliografisk träff 2016-12-15

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.

Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-16-0342

Bibliografisk träff 2016-02-20

C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.

Liu M, Gu P, Guo W, Fan X.

Tumour Biol · journal article · DOI 10.1007/s13277-015-4598-1

Bibliografisk träff 2014-08-29

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-14-0147

Bibliografisk träff 2014-06-01

Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.

Keen HG, Ricketts SA, Maynard J, Logie A, Odedra R, Shannon AM, Wedge SR, Guichard SM.

Mol Imaging Biol · journal article · DOI 10.1007/s11307-013-0705-0

Bibliografisk träff 2014-04-17

HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.

Chen SM, Guo CL, Shi JJ, Xu YC, Chen Y, Shen YY, Su Y, Ding J, Meng LH.

Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.28880

Bibliografisk träff 2014-02-15

mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma.

Zhao L, Teng B, Wen L, Feng Q, Wang H, Li N, Wang Y, Liang Z.

Int J Clin Exp Med · research-article; journal article

Bibliografisk träff 2014-01-23

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/bcr3604

Bibliografisk träff 2014-01-02

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Sharma S, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH.

Mol Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.molonc.2013.12.014

Bibliografisk träff 2013-12-02

AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma.

Hu M, Huang H, Zhao R, Li P, Li M, Miao H, Chen N, Chen M.

Oncol Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/or.2013.2890

Bibliografisk träff 2013-10-16

Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.

Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1074/jbc.m113.495986

Bibliografisk träff 2013-10-05

The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.

Li Q, Song XM, Ji YY, Jiang H, Xu LG.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2013.09.130

Bibliografisk träff 2013-01-18

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2013.01.019

Bibliografisk träff 2012-12-04

The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells.

Li S, Li Y, Hu R, Li W, Qiu H, Cai H, Wang S.

Oncol Lett · research-article; journal article · DOI 10.3892/ol.2012.1058

Bibliografisk träff 2011-04-01

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Marshall G, Howard Z, Dry J, Fenton S, Heathcote D, Gray N, Keen H, Logie A, Holt S, Smith P, Guichard SM.

Biochem Soc Trans · review; evaluation study; journal article · DOI 10.1042/bst0390456